Navigation Links
TriLink BioTechnologies, Inc. Announces Sales and License Agreement With Glen Research Corporation for CleanAmp(TM) Amidites
Date:6/24/2009

SAN DIEGO, June 24 /PRNewswire/ -- TriLink BioTechnologies (TriLink), announced that it has signed a sales and license agreement with Glen Research Corporation to sell TriLink's CleanAmp(TM) Amidites. Glen Research can now sell the patented CleanAmp(TM) Amidites produced by TriLink to third parties for use in the production of CleanAmp(TM) Primers.

TriLink's CleanAmp(TM) technology offers a less expensive approach to high stringency PCR. CleanAmp(TM) is a unique solution, where the primer or dNTP components of the PCR reaction mix, rather than the enzymes are modified. Making the CleanAmp(TM) Amidites available through Glen Research allows institutions with oligonucleotide synthesis capabilities to manufacture CleanAmp(TM) Primers in-house. Learn more at www.trilinkbiotech.com/cleanamp.

"Glen Research is dedicated to bringing the very best research products to the oligonucleotide synthesis market. So we are delighted to be able to offer CleanAmp(TM) Amidites in partnership with TriLink. We feel that the CleanAmp(TM) Amidites will make an excellent addition to our repertoire of products for DNA research," said Glen Research President/CEO, Dr. Hugh Mackie.

"TriLink and Glen Research have a long standing relationship built on a shared interest in advancing science through the highest quality reagents and technical expertise. We feel Glen Research is the perfect partner for bringing CleanAmp(TM) Amidites to the marketplace," said TriLink CEO, Dr. Richard Hogrefe.

About TriLink

TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 90 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at http://www.trilinkbiotech.com. For more information contact:

    TriLink BioTechnologies
    Shawna Leaver, 858-546-0004
    sleaver@trilinkbiotech.com

About Glen Research

Glen Research offers a wide range of phosphoramidites and solid supports for the chemical synthesis, modification, labelling and purification of DNA and RNA oligonucleotides. Glen Research's products support the development of novel strategies for use in diagnostics, sequencing and therapeutics. Founded in 1987, Glen Research is a privately held firm based in Sterling, Virginia. For more information about the firm and products, call 703-437-6191, email support@glenres.com, or visit our web site at http://www.glenres.com.


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AFIT Accelerated Flight & Instrument Training Announces New Accelerated Flight Training Programs For Cirrus Aircraft Equipped With New Perspective Avionics by Garmin (CSIP)
2. BD Announces CE Marking of BD ProbeTec™ Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
3. Hanger Orthopedic Group, Inc. Announces Second Quarter 2009 Earnings Release Conference Call
4. Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings
5. Atlantic Pharmaceuticals, Inc. Announces Completion of Successful Pre-IND Meeting with FDA for Abuse Deterrent Narcotic
6. Go Healthy Announces Association With Business Development Firm
7. New York City Chiropractor Announces New State-Of-The-Art Facility, Website
8. Cogdell Spencer Announces Chief Executive Officer Frank C. Spencer Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in the Carolinas
9. Microsoft Announces Winners of the 2009 Pharmaceutical and Life Sciences Innovation Awards
10. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
11. China Pharma Holdings, Inc. Announces SFDA Approval for Rosuvastatin Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... founder of CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda ... CitiDent offers a complete range of oral health care, including general dentistry, cosmetic ...
(Date:2/5/2016)... , ... February 05, 2016 , ... In sleep, when ... as a dream. A hallmark feature of patients with eating disorders is significant self-criticism, ... eating disorder behaviors and obsessions are regarded as maladaptive means for coping with this ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... manufactures practical mobile kitchens, recently announced the debut of their latest mobile kitchen ... Mobile Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology: